Table 2.

IDUA activity in different organs of MPS I mice treated with NEP/pIDUA_A or NEP/pIDUA_E

Treatment	IDUA activity (nmol/h/mg of protein)
	Lung	Spleen	Liver	Kidney
30 μg/2 daysa
NEP/pIDUAA	1.36±0.13*	0.10±0.01	0.73±0.03*	0.59±0.10*
NEP/pIDUAE	0.39±0.07	0.17±0.02*	1.10±0.03*	0.59±0.02*
30 μg/7 days
NEP/pIDUAA	0.24±0.02	0.10±0.02	0.52±0.07	0.18±0.04
NEP/pIDUAE	0.27±0.04	0.09±0.03	0.67±0.09*	0.18±0.01
60 μg/2 days
NEP/pIDUAA	0.28±0.03	0.14±0.01	0.48±0.06	0.24±0.03
NEP/pIDUAE	0.27±0.05	0.18±0.05	0.61±0.03*	0.28±0.03
60 μg/7 days
NEP/pIDUAA	0.41±0.04*	0.12±0.05	0.55±0.05*	0.29±0.10
NEP/pIDUAE	0.42±0.06*	0.03±0.008	0.54±0.04*	0.23±0.03
MPS I (nontreated)	0.26±0.02	0.10±0.01	0.35±0.06	0.25±0.03

Notes: Results represent the mean ± standard error of the mean.

^*Difference between treated and nontreated MPS I mice (Student’s t-test, P<0.05).

^aData from Fraga et al.⁷

Abbreviations: MPS I, mucopolysaccharidosis type I; NEP, PEGylated nanoemulsion.